Protocol Ledger

NCT05058651 · Phase II/III · RECRUITING

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Interventional Phase II/III clinical trial protocol NCT05058651 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-28 Enrollment: 189 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05058651
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)189 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05058651
Protocol FieldVerified Registry Value
NCT IdentifierNCT05058651
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment189 participants (ESTIMATED)
Registered Start Date2022-06-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05058651
Hospital Research SiteLocationSite Profile
Alaska Women's Cancer CareAnchorage, AKOpen Hospital Dossier ->
Cancer Center at Saint Joseph'sPhoenix, AZOpen Hospital Dossier ->
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Kaiser Permanente-AnaheimAnaheim, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI